## **Raquel Largo**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/729731/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 2003, 11, 290-298.	1.3	341
2	Osteoarthritis associated with estrogen deficiency. Arthritis Research and Therapy, 2009, 11, 241.	3.5	236
3	Subchondral bone as a key target for osteoarthritis treatment. Biochemical Pharmacology, 2012, 83, 315-323.	4.4	220
4	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney International, 2001, 59, 2222-2232.	5.2	213
5	TLR4 signalling in osteoarthritis—finding targets for candidate DMOADs. Nature Reviews Rheumatology, 2015, 11, 159-170.	8.0	188
6	Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Research and Therapy, 2010, 12, R152.	3.5	180
7	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. American Journal of Physiology - Renal Physiology, 2001, 281, F38-F47.	2.7	155
8	Activation of NF-κB in Tubular Epithelial Cells of Rats With Intense Proteinuria. Hypertension, 2001, 37, 1171-1178.	2.7	155
9	Effects and Interactions of Endothelin-1 and Angiotensin II on Matrix Protein Expression and Synthesis and Mesangial Cell Growth. Hypertension, 1996, 27, 885-892.	2.7	138
10	Oxidative stress, autophagy, epigenetic changes and regulation by miRNAs as potential therapeutic targets in osteoarthritis. Biochemical Pharmacology, 2016, 108, 1-10.	4.4	124
11	Histopathological correlation of cartilage swelling detected by magnetic resonance imaging in early experimental osteoarthritis. Osteoarthritis and Cartilage, 2004, 12, 878-886.	1.3	120
12	Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. Skeletal Radiology, 2006, 35, 34-41.	2.0	118
13	ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney International, 1995, 48, 1778-1791.	5.2	113
14	Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis and Cartilage, 2007, 15, 69-77.	1.3	102
15	Characterization of a new experimental model of osteoporosis in rabbits. Journal of Bone and Mineral Metabolism, 2008, 26, 53-59.	2.7	99
16	Angiotensin-Converting Enzyme Is Upregulated in the Proximal Tubules of Rats With Intense Proteinuria. Hypertension, 1999, 33, 732-739.	2.7	98
17	Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis and Cartilage, 2011, 19, 1228-1236.	1.3	98
18	Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Sixâ€Month Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Clinical Trial. Arthritis and Rheumatology, 2017, 69, 77-85.	5.6	94

#	Article	lF	CITATIONS
19	Lipid Transport and Metabolism in Healthy and Osteoarthritic Cartilage. International Journal of Molecular Sciences, 2013, 14, 20793-20808.	4.1	89
20	Osteoarthritis: a progressive disease with changing phenotypes. Rheumatology, 2014, 53, 1-3.	1.9	87
21	Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 1264-1274.	6.7	85
22	The Increase in O-Linked N-Acetylglucosamine Protein Modification Stimulates Chondrogenic Differentiation Both in Vitro and in Vivo. Journal of Biological Chemistry, 2012, 287, 33615-33628.	3.4	80
23	Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. Biochemical Pharmacology, 2019, 165, 24-32.	4.4	72
24	Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Annals of the Rheumatic Diseases, 2006, 65, 998-1005.	0.9	70
25	An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney International, 1996, 50, 962-972.	5.2	67
26	Targeting of chondrocyte plasticity via connexin43 modulation attenuates cellular senescence and fosters a pro-regenerative environment in osteoarthritis. Cell Death and Disease, 2018, 9, 1166.	6.3	67
27	Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. BMC Musculoskeletal Disorders, 2015, 16, 226.	1.9	61
28	SDF-1 signaling: a promising target in rheumatic diseases. Expert Opinion on Therapeutic Targets, 2014, 18, 1077-1087.	3.4	50
29	Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. Frontiers in Physiology, 2018, 9, 409.	2.8	50
30	Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H268-H276.	3.2	49
31	RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Arthritis Research and Therapy, 2012, 14, R149.	3.5	49
32	Renal expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in a rat model of tubulointerstitial damage. Kidney International, 1999, 55, 82-90.	5.2	48
33	Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. British Journal of Pharmacology, 2008, 154, 843-851.	5.4	47
34	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1523-1525.	0.9	47
35	A fibrin based model for rheumatoid synovitis. Annals of the Rheumatic Diseases, 2003, 62, 1135-1138.	0.9	45
36	Measures of body mass and of obesity from infancy to adulthood and their appropriate transformation. Annals of Human Biology, 1994, 21, 111-125.	1.0	44

#	Article	IF	CITATIONS
37	Increased synovial lipodystrophy induced by high fat diet aggravates synovitis in experimental osteoarthritis. Arthritis Research and Therapy, 2017, 19, 264.	3.5	44
38	Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis and Cartilage, 2008, 16, 1484-1493.	1.3	43
39	Nonsteroidal antiinflammatory drugs and prostaglandin E <sub>2</sub> modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis and Rheumatism, 2010, 62, 478-488.	6.7	42
40	EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1Â in synovial fibroblasts. Annals of the Rheumatic Diseases, 2004, 63, 1197-1204.	0.9	40
41	An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opinion on Pharmacotherapy, 2016, 17, 1745-1756.	1.8	39
42	Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. British Journal of Pharmacology, 2017, 174, 3018-3031.	5.4	38
43	6‣hogaol inhibits chondrocytes' innate immune responses and cathepsinâ€ <scp>K</scp> activity. Molecular Nutrition and Food Research, 2014, 58, 256-266.	3.3	37
44	Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis. Annals of the Rheumatic Diseases, 2002, 61, 1027-1030.	0.9	32
45	Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblastcomparison to its effects on osteoarthritic chondrocytes. Rheumatology, 2008, 47, 627-633.	1.9	32
46	Differential effects of the antioxidant n-acetylcysteine on the production of catabolic mediators in IL-1β-stimulated human osteoarthritic synoviocytes and chondrocytes. European Journal of Pharmacology, 2009, 623, 125-131.	3.5	32
47	An OA phenotype may obtain major benefit from bone-acting agents. Seminars in Arthritis and Rheumatism, 2014, 43, 421-428.	3.4	31
48	Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis?. Maturitas, 2014, 77, 380-384.	2.4	30
49	Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. Annals of the Rheumatic Diseases, 2021, 80, 261-267.	0.9	30
50	Endothelin-1 Upregulation in the Kidney of Uninephrectomized Spontaneously Hypertensive Rats and Its Modification by the Angiotensin-Converting Enzyme Inhibitor Quinapril. Hypertension, 1997, 29, 1178-1185.	2.7	29
51	Up-regulation of parathyroid hormone-related protein in folic acid-induced acute renal failure. Kidney International, 2001, 60, 982-995.	5.2	28
52	Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis. British Journal of Rheumatology, 2003, 42, 19-25.	2.3	28
53	O-linked N-acetylglucosamine (O-GlcNAc) protein modification is increased in the cartilage of patients with knee osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, 259-263.	1.3	28
54	PTH Increases Jaw Mineral Density in a Rabbit Model of Osteoporosis. Journal of Dental Research, 2010, 89, 360-365.	5.2	27

#	Article	IF	CITATIONS
55	Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration. Arthritis Research and Therapy, 2013, 15, R81.	3.5	27
56	Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation. Arthritis and Rheumatism, 2008, 58, 2723-2734.	6.7	26
57	Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. Journal of Orthopaedic Research, 2010, 28, 812-818.	2.3	26
58	Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice. Journal of Bone and Mineral Research, 2019, 34, 923-938.	2.8	26
59	The adipokine lipocalin-2 in the context of the osteoarthritic osteochondral junction. Scientific Reports, 2016, 6, 29243.	3.3	25
60	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nature Communications, 2019, 10, 797.	12.8	24
61	Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis. Scientific Reports, 2017, 7, 6311.	3.3	23
62	Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. Bone and Joint Research, 2018, 7, 58-68.	3.6	23
63	Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis Journal of the American Society of Nephrology: JASN, 1997, 8, 756-768.	6.1	23
64	Effects of PTH [1-34] on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. Osteoarthritis and Cartilage, 2012, 20, 1619-1630.	1.3	22
65	Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney International, 2001, 59, 2222.	5.2	22
66	The combined therapy with chondroitin sulfate plus glucosamine sulfate or chondroitin sulfate plus glucosamine hydrochloride does not improve joint damage in an experimental model of knee osteoarthritis in rabbits. European Journal of Pharmacology, 2017, 794, 8-14.	3.5	21
67	Platelet-activating factor stimulates gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta Journal of the American Society of Nephrology: JASN, 1997, 8, 1266-1275.	6.1	21
68	Unexpected Bone Formation Produced by RANKL Blockade. Trends in Endocrinology and Metabolism, 2017, 28, 695-704.	7.1	20
69	Chondrocyte enlargement is a marker of osteoarthritis severity. Osteoarthritis and Cartilage, 2019, 27, 1229-1234.	1.3	19
70	Sequential changes of parathyroid hormone related protein (PTHrP) in articular cartilage during progression of inflammatory and degenerative arthritis. Annals of the Rheumatic Diseases, 2004, 63, 917-922.	0.9	18
71	Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis. Osteoarthritis and Cartilage, 2010, 18, S17-S23.	1.3	18
72	Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1β, but not by TNFα. Rheumatology International, 2007, 27, 911-917.	3.0	16

#	Article	IF	CITATIONS
73	Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?. Annals of the Rheumatic Diseases, 2020, 79, 1261-1263.	0.9	16
74	Short-term and long-term variability of standard deviation scores for size in children. Annals of Human Biology, 2002, 29, 202-218.	1.0	15
75	Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. British Journal of Pharmacology, 2010, 161, 1012-1022.	5.4	14
76	Disorganization of chondrocyte columns in the growth plate does not aggravate experimental osteoarthritis in mice. Scientific Reports, 2020, 10, 10745.	3.3	14
77	Glomerular up-regulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. Kidney International, 1996, 50, 908-919.	5.2	13
78	Tight blood pressure control decreases apoptosis during renal damage. Kidney International, 2004, 65, 811-822.	5.2	13
79	Setting up distinctive outcome measures for each osteoarthritis phenotype. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093796.	2.7	13
80	Purinergic System Signaling in Metainflammation-Associated Osteoarthritis. Frontiers in Medicine, 2020, 7, 506.	2.6	13
81	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 1640-1646.	0.9	12
82	DXA in the assessment of subchondral bone mineral density in knee osteoarthritis—A semi-standardized protocol after systematic review. Seminars in Arthritis and Rheumatism, 2015, 45, 275-283.	3.4	11
83	Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis. Journal of Inflammation, 2019, 16, 2.	3.4	11
84	Modulation of the Inflammatory Process by Hypercholesterolemia in Osteoarthritis. Frontiers in Medicine, 2020, 7, 566250.	2.6	11
85	Expression of the peptide C4b-binding protein  in the arthritic joint. Annals of the Rheumatic Diseases, 2006, 65, 1279-1285.	0.9	8
86	The reverse glucosamine sulfate pathway: application in knee osteoarthritis. Expert Opinion on Pharmacotherapy, 2007, 8, 215-225.	1.8	8
87	Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. Osteoarthritis and Cartilage, 2010, 18, S12-S16.	1.3	8
88	6â€ <b>s</b> hogaol (enexasogoal) treatment improves experimental knee osteoarthritis exerting a pleiotropic effect over immune innate signalling responses in chondrocytes. British Journal of Pharmacology, 2022, 179, 5089-5108.	5.4	8
89	Is lecturing in Rheumatology Satellite Symposia a male attribute?. Rheumatology International, 2014, 34, 287-288.	3.0	7
90	Editorial: Inflammation and Biomarkers in Osteoarthritis. Frontiers in Medicine, 2021, 8, 727700.	2.6	7

#	Article	IF	CITATIONS
91	ATP transporters in the joints. Purinergic Signalling, 2021, 17, 591-605.	2.2	7
92	Aromatase expression in human chondrocytes: An induction due to culture. Maturitas, 2016, 85, 27-33.	2.4	6
93	A subgroup of lupus patients with nephritis, innate T cell activation and low vitamin D is identified by the enhancement of circulating MHC class I-related chain A. Clinical and Experimental Immunology, 2019, 196, 336-344.	2.6	6
94	Endothelin-1 Expression During Early Response After Antigen Challenge in Brown–Norway Rats. Pulmonary Pharmacology and Therapeutics, 1998, 11, 215-219.	2.6	5
95	Does oral glucosamine prevent subchondral bone loss in an animal model of osteoarthritis? Comment on the article by Wang et al. Arthritis and Rheumatism, 2008, 58, 635-635.	6.7	5
96	Blocking chondrocyte hypertrophy in conditional <i>Evc</i> knockout mice does not modify cartilage damage in osteoarthritis. FASEB Journal, 2022, 36, e22258.	0.5	5
97	Studies of Piroxicam Absorption by Oral Mucosa. Arzneimittelforschung, 2002, 52, 385-387.	0.4	4
98	Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. Therapy: Open Access in Clinical Medicine, 2010, 7, 591-604.	0.2	4
99	Validation of Musculoskeletal Ultrasound in the Assessment of Experimental Gout Synovitis. Ultrasound in Medicine and Biology, 2018, 44, 1516-1524.	1.5	4
100	Treating osteoporotic osteoarthritis, or the art of cutting a balding man's hair. Osteoarthritis and Cartilage, 2020, 28, 239-241.	1.3	4
101	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in NaÃ <sup>-</sup> ve HIV Patients. International Journal of Molecular Sciences, 2020, 21, 3590.	4.1	4
102	Subchondral bone remodelling and osteoarthritis. Arthritis Research and Therapy, 2012, 14, .	3.5	3
103	Chondroitin sulfate — CONCEPT clear, uncertainties unchanged. Nature Reviews Rheumatology, 2017, 13, 576-577.	8.0	3
104	Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor. International Journal of Molecular Sciences, 2021, 22, 11490.	4.1	3
105	244 OSTEOARTHRITIS LEADS TO INCREASED LEVELS OF PROTEIN O-LINKED N-ACETYLGLUCOSAMINE IN THE CARTILAGE. Osteoarthritis and Cartilage, 2010, 18, S111-S112.	1.3	2
106	Study of the O-linked-N-acetyl-glucosaminylation of proteins induced by high doses of glucosamine and its correlation with osteoarthritis progression. Osteoarthritis and Cartilage, 2012, 20, S126.	1.3	2
107	The ginger derivate 6-shogaol as a treatment in osteoarthritis. Modulation of chondrocyte hypertrophy and matrix calcification. Osteoarthritis and Cartilage, 2018, 26, S73-S74.	1.3	2
108	Joint obesity as a pathogenic factor in osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 1239-1241.	1.3	2

Raquel Largo

#	Article	IF	CITATIONS
109	RANKL produced by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Annals of the Rheumatic Diseases, 2012, 71, A68.3-A69.	0.9	1
110	Visfatin: a new player in rheumatic diseases. Immunometabolism, 2013, 1, .	6.0	1
111	Muscle alterations in an experimental model of chronic arthritis. Osteoarthritis and Cartilage, 2016, 24, S345.	1.3	1
112	Chondroitin sulfate plus glucosamine sulfate does not show superiority over placebo in a randomised, double blind, placebo-controlled clinical trial in patients with knee osteoarthritis. Osteoarthritis and Cartilage, 2016, 24, S48-S49.	1.3	1
113	FRI0529â€SPREAD OF SENESCENCE AND JOINT INFLAMMATION VIA CONNEXIN43-POSITIVE EXOSOMES RELEASED BY OSTEOARTHRITIC CHONDROCYTES. , 2019, , .		1
114	Bone deleterious effects of different nrtis in treatment-naÃ⁻ve HIV patients after 12 and 48 weeks of treatment. Current HIV Research, 2021, 19, .	0.5	1
115	089 PTH IMPROVES SYNOVITIS IN AN EXPERIMENTAL MODEL OF OSTEOARTHRITIS PRECEDED BY OSTEOPOROSIS. Osteoarthritis and Cartilage, 2010, 18, S47.	1.3	0
116	Effects of CTLA4-Ig on monocyte/macrophage differentiation and cytokine production. Annals of the Rheumatic Diseases, 2011, 70, A68-A69.	0.9	0
117	O-Glcnac protein modification stimulates chondrogenesis in vitro and chondrocyte hypertrophy in mouse. Annals of the Rheumatic Diseases, 2012, 71, A71.1-A71.	0.9	0
118	6-Shogaol inhibits cathepsin-K activity and has anticatabolic and anti-inflammatory properties in stimulated chondrocytes. Annals of the Rheumatic Diseases, 2012, 71, A68.2-A68.	0.9	0
119	Does RANKL produced by articular chondrocytes actively participate in juxta-articular bone loss related to chronic arthritis?. Bone, 2012, 50, S97.	2.9	0
120	Anti-inflammatory and anti-resoptive properties of ginger derivatives. Bone, 2012, 50, S99.	2.9	0
121	Rankl produced by articular chondrocytes induces bone loss associated with arthropathies. Osteoarthritis and Cartilage, 2012, 20, S65-S66.	1.3	0
122	Identification of an extracelular o-n-acetyl-glycosylase responsible for an increased level of O-linked n-acetylglucosamine modified proteins in the cartilage of patients with osteoarthritis. Osteoarthritis and Cartilage, 2012, 20, S118.	1.3	0
123	Functional estrogen biosynthesis machinery is expressed in human postmenopausic osteoarthritis chondrocytes. Osteoarthritis and Cartilage, 2012, 20, S141.	1.3	0
124	O-GlcNAc protein modification stimulates chondrogenesis in vitro and chondrocyte hypertrophy in mouse. Osteoarthritis and Cartilage, 2012, 20, S150.	1.3	0
125	CientÂficos espa±oles con los Dres. Greg Winter y Richard A. Lerner, premios PrÃncipe de Asturias en Investigación CientÂfica y Técnica 2012. Inmunologia (Barcelona, Spain: 1987), 2013, 32, 70-74.	0.1	0
126	FRI0040â€Transitional zones displacement of the subchondral bone layers in a model of osteoporosis and osteoarthritis in rabbits. Annals of the Rheumatic Diseases, 2013, 72, A381.2-A381.	0.9	0

#	Article	IF	CITATIONS
127	The procatabolic cytokine interleukin-1 alfa induces a dysregulation of o-linked n-acetylglucosamine modified proteins in human osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 2014, 22, S171-S172.	1.3	0
128	Biological role of the O-linked N-acetylglucosamine modified proteome in human osteoarthritic cartilage. Osteoarthritis and Cartilage, 2014, 22, S132.	1.3	0
129	AB0137â€Jak Inhibition by Tofacitinib Improves Rheumatoid Cachexia in a Rabbit Experimental Model That Reproduces the Lipid Paradox in Humans. Annals of the Rheumatic Diseases, 2015, 74, 936.3-937.	0.9	Ο
130	AB0106â€The Small Gtpase Rhoa Signalling is Upregulated in the Cartilage of Patients with Knee Osteoarthritis Through the Phosphorylation of Myosin Light-Chain (MLC) Phosphatase Regulatory Unit MYPT-1 Induced by ERK: In Vivo and in Vitro Studies. Annals of the Rheumatic Diseases, 2015, 74, 926.1-926.	0.9	0
131	AB0138â€Immunomodulatory Profile of Tofacitinib in the Treatment of Chronic Arthritis in Rabbits. Annals of the Rheumatic Diseases, 2015, 74, 937.1-937.	0.9	0
132	OP0077â€Muscle Alterations in an Experimental Model of Chronic Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 97.3-98.	0.9	0
133	OP0311â€Synovial Lipodystrophy Induced by Hypercholesterolemia Aggravates Synovitis in An Experimental Model of Osteoarthritis in Rabbits. Annals of the Rheumatic Diseases, 2016, 75, 175.2-175.	0.9	Ο
134	Synovial lipodystrophy induced by hypercholesterolemia aggravates synovitis in an experimental model of osteoarthritis in rabbits. Osteoarthritis and Cartilage, 2016, 24, S67.	1.3	0
135	Reply. Arthritis and Rheumatology, 2017, 69, 2093-2094.	5.6	0
136	FRI0071â€Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. , 2017, , .		0
137	OP0186â€Tenofovir, a nucleoside analog reverse transcriptase inhibitor for treatment of hiv, promotes osteoclast differentiation and bone lost in vivo in a mechanism depending on atp release and adenosine, and dipyridamole may be a useful treatment to revert the effects. , 2017, , .		0
138	AB0102â€The ginger derivative 6-shogaol as a treatment in osteoarthritis.modulation of chondrocyte hypertrophy and matrix calcification. , 2018, , .		0
139	AB0094â€Possitive effetcs of chiropractic manipulation on subchondral bone mineral density, cartilage damage and synovial inflammation in osteoarthritic rabbits. , 2018, , .		0
140	Changes in the size of hyperthrophic chondrocytes in articular cartilage in osteoarthritis. Osteoarthritis and Cartilage, 2018, 26, S80-S81.	1.3	0
141	Response to: â€~Correspondence on "Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?' by Angelides and Manolios. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219721.	0.9	0
142	Multinucleated giant cells in synovia from people with rheumatoid arthritis or osteoarthritis. Bone Abstracts, 0, , .	0.0	0
143	AB0075â€Intraarterial injection of human adipose-derived mesenchymal stem cells (HAD-MSCS) attenuates inflammation in acute arthritis model. , 2018, ,		0
144	OP0317â€ACCURACY OF THE OMERACT DEFINITIONS FOR IDENTIFICATION OF CALCIUM PYROPHOSPHATE CRYSTALS WITH ULTRASOUND: FINAL RESULTS OF THE OMERACT US IN CPPD SUB-TASK FORCE STUDY. Annals of the Rheumatic Diseases, 2020, 79, 195.2-196.	0.9	0